ArticleInternational journal of dermatology2026
Exonic Variation in HLA-C, CFB, and TAP2 Associated With Increased Risk for Comorbid Crohn's Disease and Psoriasis.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Skin: Can Genetic Variants Predict Crohn's Disease in Psoriasis Patients?International journal of dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPsoriasis (PS) and Crohn's disease (CD) are chronic immune-mediated inflammatory diseases with overlapping immunologic mechanisms. Although comorbidity is rare, epidemiologic and genetic studies have highlighted a significant association between PS and CD.
methodsWe performed a focused exome-wide association study (ExWAS) comparing individuals with comorbid PS and CD to healthy controls (case-control design) and to individuals with PS or CD alone (within-cases design) in the UK Biobank (UKB) and performed validation analyses in the All of Us (AoU) Research Program.
resultsThe exonic architecture of comorbid PS and CD more closely resembles that of PS alone. Three protein-coding variants, including two putatively functional variants and one proxy variant, were significantly associated with comorbidity: a missense variant in HLA-C (Asn104Lys), a missense variant in CFB (Gly252Ser), and a synonymous variant in TAP2. A significantly greater proportion of individuals with comorbid disease harbored at least one risk variant in all three genes (trigenic risk variant) compared to controls and PS-only individuals in both the UKB (odds ratio [OR] = 4.52, 95% confidence interval [CI] = 1.55-10.30, p = 5.8 × 10
conclusionsThis study identifies novel exonic, protein-coding genetic variation associated with the comorbidity of PS and CD, in addition to identifying an association between combined carriage of three risk variants with comorbid disease compared to controls and PS alone in multiple datasets. These risk variants may serve as prognostic biomarkers and guide personalized biologic treatment strategies in affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.